Additionally, there is the potential to modify the underlying disease with IL-23 inhibitors
171,172,173 As for the underlying mechanism, A binds to microglial TREM2, which activates TREM2 signaling and lead to the enhanced phagocytosis of microglia
No significant adverse effects were reported in both the placebo and intervention groups (Table 3)
Effective January 1, 2026, Medi-Cal Rx is excluding coverage for GLP-1 medications prescribed for weight loss: [12] Wegovy, Zepbound, Saxenda: Completely removed from the Contract Drugs List for weight loss Ozempic, Mounjaro, Rybelsus: Restricted to Type 2 diabetes onlyweight loss claims will auto-deny Existing prior authorizations end December 31, 2025 Exceptions: Members under age 21 may still qualify via EPSDT Non-weight-loss indications (Zepbound for OSA, Wegovy for cardiovascular) may still get PA approval This does NOT affect Kaiser commercial or employer-sponsored plansonly Medi-Cal members
We connect you with licensed healthcare providers who specialize in metabolic health
How Genetic Factors May Influence Your Response to GLP-1 Drug Names Your response to any GLP-1 drug namewhether semaglutide, tirzepatide, or othersis partly shaped by genetic variations in GLP-1 receptor function, GIP signaling, and metabolism
